Pipeline: Presbyopia, night vision disturbance up next for Vyluma

, ,

Presbyopia and night vision disturbance will follow myopia as a clinical focus for Vyluma. Navneet Puri, PhD, the company’s founder, chairman, and CEO, shares what is next.